Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay

Kathryn McElhinney, Luke R. Smart, Thad Alan Howard, Alexandra Power-Hays, Russell E. Ware

Blood (2023) 142 (Supplement 1): 2530.

https://doi.org/10.1182/blood-2023-190100

Published: 2023

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Blood (2021) 138 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2021-149313

Published: 2021

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402)

Mahasweta Gooptu, MD, Haesook T. Kim, PhD, Alan Howard, PhD, Sung W. Choi, MD MS, Robert J. Soiffer, MD, Joseph H. Antin, MD, Jerome Ritz, MD PhD, Corey S. Cutler, MD MPH

Blood (2018) 132 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2018-99-115662

Published: 2018

Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Blood (2017) 130 (Supplement 1): 72.

https://doi.org/10.1182/blood.V130.Suppl_1.72.72

Published: 2017

Journal Articles

Day 100 Levels of Blood Immune Cells Are Prognostic Biomarkers for Allogeneic Hematopoietic Stem Cell Transplant Outcomes: Results from BMT CTN 0201

Shanelle M. Fernando, Brent R. Logan, PhD, Mingwei Fei, MS, Stephanie J. Lee, MD PhD, Dennis Confer, MD, Alan Howard, PhD, Shanmuganathan Chandrakasan, MD, Cynthia R. Giver, PhD, Claudio Anasetti, MD, Edmund K. Waller, MD

Blood (2017) 130 (Supplement 1): 516.

https://doi.org/10.1182/blood.V130.Suppl_1.516.516

Published: 2017

Journal Articles

Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201

Edmund K. Waller, MD, Brent R. Logan, PhD, Mingwei Fei, MS, Alan Howard, PhD, John R. Wingard, MD, Claudio Anasetti, MD, Cynthia R. Giver, PhD

Blood (2017) 130 (Supplement 1): 1972.

https://doi.org/10.1182/blood.V130.Suppl_1.1972.1972

Published: 2017

Journal Articles

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Laura F. Newell, MD, Todd E. DeFor, MS, Corey S. Cutler, MD MPH, Michael R. Verneris, MD, Bruce R. Blazar, MD, Joseph H. Antin, MD, Alan Howard, PhD, Juan Wu, Margaret L. MacMillan, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Shernan G. Holtan, MD

Blood (2016) 128 (22): 63.

https://doi.org/10.1182/blood.V128.22.63.63

Published: 2016

Journal Articles

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Parameswaran Hari, MBBS, MD, MRCP, Marcelo C Pasquini, MD, MS, Brent R. Logan, PhD, Edward A. Stadtmauer, MD, Amrita Krishnan, MD, Alan Howard, PhD, Sairah Alvi, PhD, Stephen Harding, Shelly L Carter, ScD, Vincent Rajkumar, MD, Edwin P Alyea, III, MD, Muzaffar Qazilbash, MD, Ginna G. Laport, MD, David G. Maloney, MD, PhD, Sergio Giralt, MD, David H. Vesole, MD, PhD

Blood (2011) 118 (21): 2877.

https://doi.org/10.1182/blood.V118.21.2877.2877

Published: 2011

Journal Articles

Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201

Edmund K Waller, MD PhD, Wayne A.C. Harris, Steven Devine, David L. Porter, MD, Shin Mineishi, MD, John M. McCarty, MD, Corina E Gonzalez, MD, Thomas R Spitzer, MD, Oleg I. Krijanovski, PhD, MD, Michael L. Linenberger, MD, Ann Woolfrey, MD, Alan Howard, PhD, Cathy Gurgol, Brent R. Logan, PhD, Dennis L Confer, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 1004.

https://doi.org/10.1182/blood.V118.21.1004.1004

Published: 2011

NARROW

A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402)

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Day 100 Levels of Blood Immune Cells Are Prognostic Biomarkers for Allogeneic Hematopoietic Stem Cell Transplant Outcomes: Results from BMT CTN 0201

Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only